Product Name
ERCC8, Blocking Peptide
Full Product Name
ERCC8 Peptide - C-terminal region
Product Gene Name
ERCC8 blocking peptide
[Similar Products]
Product Synonym Gene Name
ERCC8;CKN1;CSA;[Similar Products]
ERCC8 peptide (MBS3244051) is used for blocking the activity of ERCC8 antibody (MBS3219159)
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
Sequence
Synthetic peptide located within the following region: QSNFQELYSG SRDCNILAWV PSLYEPVPDD DETTTKSQLN PAFEDAWSSS
3D Structure
ModBase 3D Structure for Q13216
Form/Format
Lyophilized powder
Preparation and Storage
Add 100ul of sterile PBS. Final peptide concentration is 1 mg/ml in PBS. For longer periods of storage, store at -20 degree C. Avoid repeat freeze-thaw cycles.
Other Notes
Small volumes of ERCC8 blocking peptide vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
ERCC8 blocking peptide
This is a synthetic peptide designed for use in combination with anti-ERCC8 Antibody, made
Target Description: This gene encodes a WD repeat protein, which interacts with Cockayne syndrome type B (CSB) protein and with p44 protein, a subunit of the RNA polymerase II transcription factor IIH. Mutations in this gene have been identified in patients with hereditary disease Cockayne syndrome (CS). CS cells are abnormally sensitive to ultraviolet radiation and are defective in the repair of transcriptionally active genes. Several transcript variants encoding different isoforms have been found for this gene.
Product Categories/Family for ERCC8 blocking peptide
Peptide
Applications Tested/Suitable for ERCC8 blocking peptide
Western Blot (WB)
NCBI/Uniprot data below describe general gene information for ERCC8. It may not necessarily be applicable to this product.
NCBI Accession #
NP_000073
[Other Products]
NCBI GenBank Nucleotide #
NM_000082.3
[Other Products]
UniProt Primary Accession #
Q13216
[Other Products]
UniProt Related Accession #
Q13216[Other Products]
NCBI Official Full Name
DNA excision repair protein ERCC-8 isoform 1
NCBI Official Synonym Full Names
ERCC excision repair 8, CSA ubiquitin ligase complex subunit
NCBI Official Symbol
ERCC8??[Similar Products]
NCBI Official Synonym Symbols
CSA; CKN1; UVSS2
??[Similar Products]
NCBI Protein Information
DNA excision repair protein ERCC-8
UniProt Protein Name
DNA excision repair protein ERCC-8
UniProt Synonym Protein Names
Cockayne syndrome WD repeat protein CSA
Protein Family
DNA excision repair protein
UniProt Gene Name
ERCC8??[Similar Products]
UniProt Synonym Gene Names
CKN1; CSA??[Similar Products]
UniProt Entry Name
ERCC8_HUMAN
NCBI Summary for ERCC8
This gene encodes a WD repeat protein, which interacts with Cockayne syndrome type B (CSB) protein and with p44 protein, a subunit of the RNA polymerase II transcription factor IIH. Mutations in this gene have been identified in patients with hereditary disease Cockayne syndrome (CS). CS cells are abnormally sensitive to ultraviolet radiation and are defective in the repair of transcriptionally active genes. Several transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Mar 2014]
UniProt Comments for ERCC8
ERCC8: Substrate-recognition component of the CSA complex, a DCX (DDB1-CUL4-X-box) E3 ubiquitin-protein ligase complex, involved in transcription-coupled nucleotide excision repair. The CSA complex (DCX(ERCC8) complex) promotes the ubiquitination and subsequent proteasomal degradation of ERCC6 in a UV-dependent manner; ERCC6 degradation is essential for the recovery of RNA synthesis after transcription-coupled repair. It is required for the recruitment of XAB2, HMGN1 and TCEA1/TFIIS to a transcription- coupled repair complex which removes RNA polymerase II-blocking lesions from the transcribed strand of active genes. Defects in ERCC8 are the cause of Cockayne syndrome type A (CSA). Cockayne syndrome is a rare disorder characterized by cutaneous sensitivity to sunlight, abnormal and slow growth, cachectic dwarfism, progeroid appearance, progressive pigmentary retinopathy and sensorineural deafness. There is delayed neural development and severe progressive neurologic degeneration resulting in mental retardation. Two clinical forms are recognized: in the classical form or Cockayne syndrome type 1, the symptoms are progressive and typically become apparent within the first few years or life; the less common Cockayne syndrome type 2 is characterized by more severe symptoms that manifest prenatally. Cockayne syndrome shows some overlap with certain forms of xeroderma pigmentosum. Unlike xeroderma pigmentosum, patients with Cockayne syndrome do not manifest increased freckling and other pigmentation abnormalities in the skin and have no significant increase in skin cancer. Defects in ERCC8 are the cause of UV-sensitive syndrome type 2 (UVSS2). An autosomal recessive disorder characterized by cutaneous photosensitivity and mild freckling in the absence of neurological abnormalities or skin tumors. 2 isoforms of the human protein are produced by alternative splicing.
Protein type: DNA repair, damage; Helicase; Ubiquitin conjugating system
Chromosomal Location of Human Ortholog: 5q12.1
Cellular Component: nucleoplasm; nucleotide-excision repair complex; nuclear matrix; protein complex; nucleus
Molecular Function: DNA-dependent ATPase activity; protein binding; DNA helicase activity; ubiquitin-protein ligase activity; protein complex binding
Biological Process: proteasomal ubiquitin-dependent protein catabolic process; protein autoubiquitination; positive regulation of DNA repair; protein polyubiquitination; nucleotide-excision repair; transcription-coupled nucleotide-excision repair; response to oxidative stress; DNA repair; response to DNA damage stimulus; response to X-ray; response to UV
Disease: Cockayne Syndrome A; Uv-sensitive Syndrome 2
Research Articles on ERCC8
1. Results showed that the odds ratio for gastric cancer of the different ERCC8 rs158572 and rs158916 genotypes was not significantly increased in the observation group compared with that in the control group. By contrast, in patients with H. pylori infection, the ERCC8 rs158572 GA/GG and rs158916 TT genotypes showed a 7.921-fold and 8.021-fold increased risk of gastric cancer than the AA and CT/CC genotypes, respectively.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.